Circulating miRNAs in Women with Polycystic Ovary Syndrome: A Longitudinal Cohort Study

• Published in: Cells (Basel, Switzerland) Switzerland), 2023-03, Vol.12 (7), p.983
• Main Authors: Udesen, Pernille B, Sørensen, Anja E, Svendsen, Rikke, Frisk, Nanna L S, Hess, Anne L, Aziz, Mubeena, Wissing, Marie Louise M, Englund, Anne Lis M, Dalgaard, Louise T
• Format: Article
• Language: English
• Subjects: Analysis; Androgens; Biological markers; biomarker; Biomarkers; Care and treatment; Cholesterol; Circulating MicroRNA - genetics; circulation; Cohort analysis; Cohort Studies; Complications and side effects; Dyslipidemia; Female; Follow-Up Studies; Gastrointestinal surgery; Gene expression; Glucose; Glucose tolerance; Gonadotropin-releasing hormone; Gonadotropins; High density lipoprotein; Hormones; Humans; Immunological tolerance; Immunoregulation; Infertility; Insulin resistance; Insulin-like growth factors; Longitudinal Studies; Metabolic syndrome; MicroRNA; MicroRNAs; MicroRNAs - genetics; MicroRNAs - metabolism; miRNA; Morphology; Ovarian cancer; Ovaries; PCOS; Peptides; Pituitary (anterior); Polycystic ovary syndrome; Polycystic Ovary Syndrome - genetics; Polycystic Ovary Syndrome - metabolism; Pregnancy; Protein-tyrosine kinase; Signal transduction; Statistical analysis; Stein-Leventhal syndrome; Testosterone; Triglycerides; Wnt protein; Womens health
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells12070983

Women with polycystic ovary syndrome (PCOS) often change their metabolic profile over time to decrease levels of androgens while often gaining a propensity for the development of the metabolic syndrome. Recent discoveries indicate that microRNAs (miRNAs) play a role in the development of PCOS and constitute potential biomarkers for PCOS. We aimed to identify miRNAs associated with the development of an impaired metabolic profile in women with PCOS, in a follow-up study, compared with women without PCOS. Clinical measurements of PCOS status and metabolic disease were obtained twice 6 years apart in a cohort of 46 women with PCOS and nine controls. All participants were evaluated for degree of metabolic disease (hypertension, dyslipidemia, central obesity, and impaired glucose tolerance). MiRNA levels were measured using Taqman Array cards of 96 pre-selected miRNAs associated with PCOS and/or metabolic disease. Women with PCOS decreased their levels of androgens during follow-up. Twenty-six of the miRNAs were significantly changed in circulation in women with PCOS during the follow-up, and twenty-four of them had decreased, while levels did not change in the control group. Four miRNAs were significantly different at baseline between healthy controls and women with PCOS; miR-103-3p, miR-139-5p, miR-28-3p, and miR-376a-3p, which were decreased in PCOS. After follow-up, miR-28-3p, miR-139-5p, and miR-376a-3p increased in PCOS women to the levels observed in healthy controls. Of these, miR-139-5p correlated with total testosterone levels (rho = 0.50, p = 0.013), while miR-376-3p correlated significantly with the waist-hip ratio at follow-up (rho = 0.43, p = 0.01). Predicted targets of miR-103-3p, miR-139-5p, miR-28-3p, and miR-376a-3p were enriched in pathways associated with Insulin/IGF signaling, interleukin signaling, the GNRH receptor pathways, and other signaling pathways. MiRNAs altered during follow-up in PCOS patients were enriched in pathways related to immune regulation, gonadotropin-releasing hormone signaling, tyrosine kinase signaling, and WNT signaling. These studies indicate that miRNAs associated with PCOS and androgen metabolism overall decrease during a 6-year follow-up, reflecting the phenotypic change in PCOS individuals towards a less hyperandrogenic profile.